Basic Information
| RNALocate ID: | RLID:11003621 |
| RNA Symbol: | hsa-miR-29b-1-5p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-29b-1-star |
| RNA ID: | miRBase:MIMAT0004514 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23539611 |
| Tissue/Cell Line: | Seminal plasma |
| Method: | Microarray |
| Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002584 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID-D:11000591 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
| RLID-D:11001470 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-29b-1-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-35054 |
| MNDR | hsa-miR-29b-1-5p | Medulloblastoma | MNDR-E-MI-35055 |
| MNDR | hsa-miR-29b-1-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-35056 |
| MNDR | hsa-miR-29b-1-5p | Lymphoma | MNDR-E-MI-35057 |
| MNDR | hsa-miR-29b-1-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-35058 |
| MNDR | hsa-miR-29b-1-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-35059 |
| MNDR | hsa-miR-29b-1-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-35060 |
| MNDR | hsa-miR-29b-1-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-35061 |
| MNDR | hsa-miR-29b-1-5p | Her2-receptor positive breast cancer | MNDR-E-MI-35062 |
| MNDR | hsa-miR-29b-1-5p | Prostate cancer | MNDR-E-MI-35063 |
| MNDR | hsa-miR-29b-1-5p | Gastric cancer | MNDR-E-MI-35064 |
| MNDR | hsa-miR-29b-1-5p | Alzheimer disease | MNDR-E-MI-35065 |
| MNDR | hsa-miR-29b-1-5p | Seizures | MNDR-E-MI-35066 |
| MNDR | hsa-miR-29b-1-5p | Lung cancer | MNDR-E-MI-35067 |
| MNDR | hsa-miR-29b-1-5p | Parkinson disease | MNDR-E-MI-35068 |
| MNDR | hsa-miR-29b-1-5p | Breast cancer | MNDR-E-MI-35069 |
| MNDR | hsa-miR-29b-1-5p | Pituitary neoplasms | MNDR-E-MI-35070 |
| MNDR | hsa-miR-29b-1-5p | Pancreatic cancer | MNDR-E-MI-35071 |
| MNDR | hsa-miR-29b-1-5p | Colon cancer | MNDR-E-MI-35072 |
| MNDR | hsa-miR-29b-1-5p | Colon adenocarcinoma | MNDR-E-MI-35073 |
| MNDR | hsa-miR-29b-1-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-35074 |
| MNDR | hsa-miR-29b-1-5p | Familial ovarian cancer | MNDR-E-MI-35075 |
| MNDR | hsa-miR-29b-1-5p | Acromegaly | MNDR-E-MI-35076 |
| MNDR | hsa-miR-29b-1-5p | Prostate adenocarcinoma | MNDR-E-MI-35077 |
| MNDR | hsa-miR-29b-1-5p | Carcinoma ductal breast | MNDR-E-MI-35078 |
| MNDR | hsa-miR-29b-1-5p | Glioma | MNDR-E-MI-35079 |
| MNDR | hsa-miR-29b-1-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-35080 |
| MNDR | hsa-miR-29b-1-5p | Osteosarcoma | MNDR-E-MI-35081 |
| MNDR | hsa-miR-29b-1-5p | Mesenchymal cancer | MNDR-E-MI-35082 |
| MNDR | hsa-miR-29b-1-5p | Gastric adenocarcinoma | MNDR-E-MI-35083 |
| MNDR | hsa-miR-29b-1-5p | Pituitary adenoma | MNDR-E-MI-35084 |
| MNDR | hsa-miR-29b-1-5p | Non-small cell lung adenocarcinoma | MNDR-E-MI-35085 |
| MNDR | hsa-miR-29b-1-5p | Lung adenocarcinoma | MNDR-E-MI-35086 |
| MNDR | hsa-miR-29b-1-5p | Thyroid carcinoma | MNDR-E-MI-35087 |
| MNDR | hsa-miR-29b-1-5p | Pancreatic adenocarcinoma | MNDR-E-MI-35088 |
| MNDR | hsa-miR-29b-1-5p | Carcinoma renal cell | MNDR-E-MI-35089 |
| MNDR | hsa-miR-29b-1-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-35090 |
| MNDR | hsa-miR-29b-1-5p | Renal clear cell carcinoma | MNDR-E-MI-35091 |
| MNDR | hsa-miR-29b-1-5p | Lung small cell carcinoma | MNDR-E-MI-35092 |
| MNDR | hsa-miR-29b-1-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-35093 |
| MNDR | hsa-miR-29b-1-5p | Testicular germ cell cancer | MNDR-E-MI-35094 |
| MNDR | hsa-miR-29b-1-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-35095 |
| MNDR | hsa-miR-29b-1-5p | Breast invasive carcinoma | MNDR-E-MI-35096 |
| MNDR | hsa-miR-29b-1-5p | Hepatocellular carcinoma | MNDR-E-MI-35097 |
| MNDR | hsa-miR-29b-1-5p | Embryonal cancer | MNDR-E-MI-35098 |
| MNDR | hsa-miR-29b-1-5p | Familiar ovarian carcinoma | MNDR-E-MI-35099 |
| MNDR | hsa-miR-29b-1-5p | B-cell lymphoma | MNDR-E-MI-35100 |
| MNDR | hsa-miR-29b-1-5p | Malignant pleural mesothelioma | MNDR-E-MI-35101 |
| MNDR | hsa-miR-29b-1-5p | Hodgkin lymphoma | MNDR-E-MI-35102 |
| MNDR | hsa-miR-29b-1-5p | Skin cutaneous melanoma | MNDR-E-MI-35103 |
| MNDR | hsa-miR-29b-1-5p | Skin melanoma | MNDR-E-MI-35104 |
| MNDR | hsa-miR-29b-1-5p | Colorectal cancer | MNDR-E-MI-35105 |
| MNDR | hsa-miR-29b-1-5p | Multiple myeloma | MNDR-E-MI-35106 |
| MNDR | hsa-miR-29b-1-5p | Wounds and injuries | MNDR-E-MI-35107 |
| MNDR | hsa-miR-29b-1-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-35108 |
| MNDR | hsa-miR-29b-1-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-35109 |
| MNDR | hsa-miR-29b-1-5p | Stroke lacunar | MNDR-E-MI-35110 |
| MNDR | hsa-miR-29b-1-5p | Breast cancer her3+ negative | MNDR-E-MI-35111 |
| MNDR | hsa-miR-29b-1-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-35112 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | AKT3 | Homo sapiens | RR00067431 |
TOP